Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : Morgan Stanley Lowers Price Target on Novartis, Maintains Overweight/In-Line Recommendation

07/27/2021 | 08:44am EDT


ę MT Newswires 2021
All news about NOVARTIS AG
09/23VC DAILY : Biotechs Seek New Skill Set From Scientists Entering Field
DJ
09/22GLOBAL MARKETS LIVE : Airbus, Fedex, Google, McDonald's, Roche...
09/22NOVARTIS : Zacks Lowers Price Target on Novartis, Maintains Neutral Recommendation
MT
09/21NOVARTIS : Launches Entresto Patent Infringement Case Against Seven Indian Pharma Groups
MT
09/21INCYTE : FDA approves Incyte's eczema cream with boxed warnings
RE
09/21INCYTE : FDA approves Incyte's eczema cream
RE
09/21GLOBAL MARKETS LIVE : Vivendi, EssilorLuxottica, Compass, StageCoach, Allianz...
09/21NOVARTIS : Acquires Arctos Medical to Expand Optogenetics Portfolio
MT
09/21NOVARTIS : Boosts Optogenetics Portfolio With Arctos Medical Acquisition
MT
09/21Novartis buys gene therapy firm Arctos Medical in vision loss treatment push
RE
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 992 M - -
Net income 2021 10 094 M - -
Net Debt 2021 22 236 M - -
P/E ratio 2021 18,3x
Yield 2021 3,93%
Capitalization 186 B 186 B -
EV / Sales 2021 4,01x
EV / Sales 2022 3,74x
Nbr of Employees 109 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 83,22 $
Average target price 102,33 $
Spread / Average Target 23,0%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-8.00%186 020
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037